skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration
This white paper from Datamonitor Healthcare identifies and discusses key highlights from the 55th annual meeting of the American Society of Hematology (ASH), giving you greater insight and analysis from the conference.

Highlights from this whitepaper include:

  • CLL11 trial demonstrates superiority of Rituxan’s glycoengineered successor
  • Revlimid shows a significant clinical benefit in newly diagnosed multiple myeloma patient
  • Idelalisib proves an effective therapy for relapsed or refractory chronic lymphocytic leukemia
ASH Whitepaper

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907
  • Japan            : +81 3-6273-4257

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: